Thermo Fisher Scientific Reports Q2 2023 Revenue Dip, Adjusts Full-Year Forecast
US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has released its financial results...
AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research
AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research...
GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance
UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the...
Everest Medicines Launches Xerava Antibiotic in China, Marking Commercial Milestone
Everest Medicines (HKG: 1952) has announced the commercial launch of its Xerava (eravacycline) antibiotic in...
Jiangsu Recbio’s Shingles Vaccine REC610 Accepted for Review by China’s NMPA
Jiangsu Recbio Technology Co., Ltd, a China-based company, has announced that the National Medical Products...
Mirxes Holding Company Secures USD 50 Million in Series D Financing for RNA Technology
Mirxes Holding Company Ltd, a Singapore-headquartered RNA technology company specializing in blood-based miRNA test kit...
Shanghai Henlius Completes Phase I/II Study for Anti-VEGF mAb HLX04-O in Wet AMD
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary, Shanghai Henlius Biotech, Inc....
Innovent Biologics’ Altruist Biologics Partners with Longbio Pharma in RMB 500 Million Deal
Altruist Biologics, the Contract Development and Manufacturing Organization (CDMO) unit of China-based Innovent Biologics, Inc. (HKG:...
SSY Group Ltd Receives NMPA Approval for Stiripentol Dry Suspension for Dravet Syndrome
China-based SSY Group Ltd (HKG: 2005) has announced that it has received marketing approval from...
Novo Nordisk’s Turoctocog Alfa Pegol for Hemophilia A Accepted for Review by China’s CDE
The Center for Drug Evaluation (CDE) in China has indicated on its website that the...
Sisram Medical’s Alma Veil Launches in the US for Vascular Lesion Treatment
Alma Lasers, a subsidiary of Sisram Medical (HKG: 1696), has announced the commercial availability of...
AstraZeneca’s Eplontersen Gains Tacit Approval from CDE for ATTR-CM Clinical Study
The Center for Drug Evaluation (CDE) website indicates that UK pharmaceutical major AstraZeneca’s (AZ, NASDAQ:...
Kanova Biopharma Secures Over RMB 100 Million in Financing for Autoimmune and Oncology Pipeline
Kanova Biopharma, a Suzhou-based developer of antibodies focused on autoimmune diseases and oncology, has reportedly...
Boehringer Ingelheim Gets NMPA Approval for Phase II Study of BI 764532 in SCLC
Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical Products...
HanchorBio’s HCB101 Receives WFDA Approval for Multi-Region Clinical Study
Taiwan-based HanchorBio has announced that it has received approval from the Taiwan Food and Drug...
Sosei Heptares Acquires Idorsia’s Korea and Japan Units in JPY 65 Billion Deal
Japan-based Sosei Group Corporation (TYO: 4565) has announced that its subsidiary, Sosei Heptares, has acquired...
InnoCare Pharma’s ICP-723 Receives NMPA Approval for Pediatric Clinical Study
Beijing InnoCare Pharma (HKG: 9969), a China-based biotech company specializing in cancer and autoimmune diseases,...
Boehringer Ingelheim and Eli Lilly’s Jardiance Approved by EC for Chronic Kidney Disease
Germany-based Boehringer Ingelheim and its US partner Eli Lilly & Co., (NYSE: LLY), have reported...
Biogen’s Q2 2023 Report Reveals Struggles with Aduhelm and 1,000 Job Cuts
US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has released its financial report for the second quarter...
FDA Approves Daiichi Sankyo’s Vanflyta for FLT3-ITD Positive AML Maintenance Treatment
The US Food and Drug Administration (FDA) has granted clearance to Japan-based Daiichi Sankyo (TYO:...